AMDL Subsidiary Donates Pharmaceuticals in China Earthquake Relief Effort
May 14 2008 - 7:55PM
PR Newswire (US)
TUSTIN, Calif., May 14 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi, and Jilin, China, is a vertically integrated
specialty pharmaceutical company. Along with its subsidiary Jade
Pharmaceutical Inc. (JPI), AMDL engages in the research,
development, manufacture, and marketing of diagnostic,
pharmaceutical, nutritional supplement, and cosmetic products
currently in China. The Company today announced that JPI has
donated various pharmaceutical products valued at more than
$70,000, to the China Red Cross (Chengdu Branch) to provide medical
support to the victims of the recent earthquake located in Shichuan
Province, which devastated portions of China. "Not only did our JPI
management make this significant donation valued at more than
$70,000, it initiated a special trip to Sichuan to ensure that the
drugs reached the proper destinations," said Gary Dreher, CEO of
AMDL. "The initiative taken by JPI signals its awareness and
enthusiasm for its social responsibility. We do not expect that
this earthquake will have any negative impact on sales of JJB and
or YYB products, in fact, certain products may experience a higher
than normal sales growth rate due to the disaster." About Jade
Pharmaceutical: JPI has access to the fastest growing
pharmaceutical and consumer market in the world: China. AMDL,
through its subsidiaries, Jade currently manufactures large volume
injection fluids, tablets and other related products, holding
licenses for 133 products. It also manufactures 107 generic, over
the counter and supplemental pharmaceutical products under
certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be
obtained at http://www.amdl.com/. Forward-Looking Statements This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from
those projected in such forward-looking statements. The Company
cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct
Line: 949.707.5365 VoiceMail: 714.505.4460 DATASOURCE: AMDL, Inc.
CONTACT: Mr. Paul Knopick, +1-949-707-5365, voicemail,
+1-714-505-4460, for AMDL Investor Relations Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024